Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Half Year Ended June 30, 2021
August 16, 2021
Share
Sunmax Biotechnology Co., Ltd. announced earnings results for the second quarter and half year ended June 30, 2021. For the second quarter, the company announced total revenue was TWD 234.735 million compared to TWD 196.128 million a year ago. Operating income was TWD 76.498 million compared to TWD 91.457 million a year ago. Net income was TWD 44.522 million compared to TWD 60.978 million a year ago. Basic earnings per share was TWD 0.81 compared to TWD 1.12 a year ago.
For the half year, total revenue was TWD 501.782 million compared to TWD 367.018 million a year ago. Operating income was TWD 166.923 million compared to TWD 187.988 million a year ago. Net income was TWD 107.457 million compared to TWD 117.280 million a year ago. Basic earnings per share was TWD 1.97 compared to TWD 2.15 a year ago.
SunMax Biotechnology Co., Ltd. is a Taiwan-based company principally engaged in research, development, production and distribution of collagen implants and related products. The Company's major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, as well as medical collagen application equipment. Its products are applied in medical and beauty care industrials. The Company distributes its products principally in Taiwan, Mainland China and other regions.